共 50 条
Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting
被引:18
|作者:
Armstrong, April W.
[1
]
Gelfand, Joel M.
[2
]
Boehncke, Wolf-Henning
[3
]
Armstrong, Ehrin J.
[4
]
机构:
[1] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95816 USA
[2] Univ Penn Hlth Syst, Philadelphia, PA USA
[3] Univ Hosp Geneva, Dept Dermatol, Geneva, Switzerland
[4] Univ Calif Davis, Div Cardiovasc Med, Sacramento, CA 95816 USA
关键词:
CARDIOVASCULAR COMORBIDITIES;
PSORIASIS;
BIOLOGICS;
PSORIATIC ARTHRITIS;
TUMOR NECROSIS FACTOR INHIBITORS;
COMPARATIVE EFFECTIVENESS;
MYOCARDIAL-INFARCTION;
RHEUMATOID-ARTHRITIS;
INSULIN-RESISTANCE;
METABOLIC SYNDROME;
DIABETES-MELLITUS;
INCREASED RISK;
DISEASE;
ASSOCIATION;
MODERATE;
THERAPY;
D O I:
10.3899/jrheum.130457
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.
引用
收藏
页码:1434 / 1437
页数:4
相关论文